Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
about
Role of isavuconazole in the treatment of invasive fungal infectionsIsavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsRecent developments in the management of invasive fungal infections in patients with oncohematological diseasesRegulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the GoodNovel antifungal agents: a patent review (2013 - present).Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac RepolarizationThe Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.In Vitro Activity of Isavuconazole against Rasamsonia SpeciesInvasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registriesPrevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.RNAi-Based Functional Genomics Identifies New Virulence Determinants in Mucormycosis.Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases.Combination Antifungal Therapy: A Review of Current Data.Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects.Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy AdultsChallenges in microbiological diagnosis of invasive Aspergillus infections.FungiScope™ -Global Emerging Fungal Infection Registry.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.Drug development challenges and strategies to address emerging and resistant fungal pathogens.Pulmonary mucormycosis: clinical features and outcomes.Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century.Drugs in Clinical Development for Fungal Infections.New pharmacological opportunities for the treatment of invasive mould diseases.Isavuconazole: is there a need for a new antifungal?Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects.Rare fungal infectious agents: a lurking enemy.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.
P2860
Q26740837-CEBC5E21-B711-40C3-83F9-333AD864352BQ26744049-1FE85607-EB00-4C5A-9D60-78E49EB35A6FQ28067726-2604F93C-749F-45F7-80EC-B0AB0AD83629Q28077381-74831BD9-4E5E-4777-B705-CD9E39530F04Q28468531-A76AD655-67D7-454A-96A8-A2DEE27A244FQ30239745-DF24B889-0351-41C9-90A3-3AA3C810B841Q33726698-7E8C4933-BD6A-40E4-8D11-B4C2D3FDF048Q33837720-B9F25CEA-20B7-4F97-B954-174BE7CCFA0EQ34540684-9128C7E8-84DC-44EF-AC83-2AF41303B40BQ36104417-ADC7BB54-70E7-47DC-AE12-C9150A223BC2Q36189107-C4C219B3-890E-48B9-A05B-7619B1F2FCA4Q36209069-52AF6BD5-D668-41BD-B723-10AFA691817BQ36255871-BFD2FD82-2CE1-44DD-9861-D049E26903A0Q36353625-4A77C87D-7F3A-453D-804B-E1FA3C6430EAQ36369805-9354A5A4-8BF7-4CFC-9231-6E5DA3DE98C1Q36396166-016FE4F6-2C0B-4089-92A5-ECAB64D62C11Q37096795-96D8236D-7836-41F7-9C14-7111AD08E080Q37150434-92914AF2-BE67-407C-9C3B-D7ACD151E414Q37631771-E970E4EC-AFCC-4CC6-964F-CC0BCB23A9A0Q37631831-E5FCFFF4-1B05-4FE8-A491-B8989B4E7AC0Q37631841-DA90FAAB-41FE-4E26-8148-B6216F91757FQ37631892-27E4F863-F1F8-46C5-B267-3054F066497BQ37631935-ABFE91D7-56D3-4E2C-BFEF-3C2D054628CDQ37659157-53B667B6-E853-4B39-A582-952FBBE1AD36Q38668606-6E112881-0C79-411D-818E-4F279B29D387Q38738090-88D07E04-3A76-4E0A-BB67-A45BC45B2619Q38758268-9D458BBD-CB6F-4A08-AA17-0F363344590BQ38798805-8E1BEE23-6E5D-4196-BFCB-B4CAA3CDBD86Q38950932-F760F2F5-A203-47E2-85FB-BA037DC767DCQ38987096-AB09A8FA-188D-4F76-ABBE-A1A08069BFD0Q39048531-4BFACC5B-2474-4ABC-B9C5-80B25F30FF80Q39067518-37D19D3B-9416-4E67-95C7-B970DF91CD6DQ40070714-26E48669-2B6E-47FF-A7D5-4413BF278BDEQ40273481-26CA189F-5839-4011-A201-FCCB14E126DDQ40273512-CD26FAEA-A74B-44D5-8C72-C5956E59C373Q40306219-BE140302-90A9-47B6-8FB0-A6EB5810AB37Q40474311-CABA70E7-CC16-4CE9-B35A-041CB47EB4B9Q42323175-C69DB46A-00E0-4381-89F3-60C58B0CD801Q46258749-3AEEEF43-841D-448B-8ADA-F1B5FC39F015Q47151374-B4D1AA33-16AB-4581-A252-06E287A4CCC9
P2860
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Isavuconazole treatment for mu ...... ial and case-control analysis.
@en
type
label
Isavuconazole treatment for mu ...... ial and case-control analysis.
@en
prefLabel
Isavuconazole treatment for mu ...... ial and case-control analysis.
@en
P2093
P50
P1476
Isavuconazole treatment for mu ...... rial and case-control analysis
@en
P2093
Achim Kaufhold
Bernhardt Zeiher
Carolyn Sasse
Galia Rahav
Galina Klyasova
George J Alangaden
George R Thompson
Ilana Oren
J Janne Vehreschild
Janice M Brown
P304
P356
10.1016/S1473-3099(16)00071-2
P50
P577
2016-03-09T00:00:00Z